Empirico, Ionis collaborate to develop antisense oligonucleotide therapeutics

This article was originally published here

Under the three-year collaboration, Empirico will use its Precision Insights Platform to determine therapeutic targets for indications and tissues, which are responsive to antisense technology. The Precision Insights

The post Empirico, Ionis collaborate to develop antisense oligonucleotide therapeutics appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply